Article
Moleculin Biotech Reports Preliminary Composite Complete Remission Rate Of 40% In Phase 2B/3 Miracle Trial's First 30 Subjects Treated, With Annamycin In Combination With Cytarabine For Refractory To Or Relapsed Acute Myeloid Leukemia After Induction Therapy
- Preliminary blinded CR rate showed 67% improvement over historical cytarabine response
- Roughly 35% of the subjects treated to date represent ventoclax regimen failures.
- First 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter; treated 35 subjects to date with another 11 identified
- Continued absence of cardiotoxicity and high efficacy expected to position Annamycin as a "significant advancement" in AML treatment
Comments
- No comments yet. Be the first to comment!